Strategies for Pancreatic Cancer-Responsive Nanodrug Platforms Targeting Tumor Hypoxic Environments.

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, largely because of its profoundly hypoxic and desmoplastic tumor microenvironment (TME), which hinders drug delivery and promotes resistance to chemotherapy, radiotherapy, and immunotherapy. Hypoxia not only serves as a therapeutic barrier, but also presents a selective vulnerability that can be exploited by smart nanocarriers. This review highlights recent advances in hypoxia-responsive nanoparticle (NP) platforms designed to overcome these barriers through four key strategies: (1) hypoxia-triggered drug release using bioreductively cleavable linkers and hypoxia-activated prodrugs; (2) surface functionalization with tumor-targeting ligands, such as aptamers and antibodies; (3) selective activation of hypoxia-activated prodrugs that become cytotoxic only under low oxygen conditions; and (4) multi-stimuli-responsive designs integrating pH, enzymatic, or exogenous triggers. Preclinical studies in PDAC models have demonstrated that these systems can achieve over two-fold tumor growth inhibition and a 60% increase in intratumoral necrosis compared with controls, validating their in vivo therapeutic potential. Furthermore, the recent integration of artificial intelligence into NP design has accelerated the optimization of hypoxia-responsive systems by enabling the rapid identification of structure-function relationships and in silico prediction of tumor-specific accumulation. Collectively, these strategies offer a promising route toward more effective, selective, and personalized nanomedicines for pancreatic cancer treatment.